PTGX
Protagonist Therapeutics, Inc
Next earnings Aug 4, 2026 (after close) · consensus $1.98 EPS, $218M rev
Last earnings -0.3% on 2026-05-05
$122.19
▲ +0.03%$122.19▲ +126.61%
over 1Y
L $49.70EODHDH $122.19
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+9.6%
1M+22.2%
3M+17.1%
YTD+40.1%
1Y+126.5%
Hold
Conviction
Horizon
Long (>12mo)
Street · 20 analysts
Buy
De-risked biotech with two partnered drugs nearing 2026 launches, but a $7.2B cap prices in approval and commercial success.
Protagonist Therapeutics is a clinical/commercial-stage biotech that is more de-risked than its loss-making financials suggest. Its two lead assets are both partnered with major pharma and at the regulatory finish line: icotrokinra (Icotyde), a first-in-class oral IL-23R peptide for psoriasis, is licensed to Johnson & Johnson, which filed a US NDA in July 2025 and expects a US launch in 2026; and rusfertide, an injectable hepcidin mimetic for polycythemia vera, is partnered with Takeda, carries Breakthrough Therapy, Fast Track and Orphan Drug designations, had its NDA filed in December 2025, and Takeda expects to launch in 2H 2026. Beyond these, a pipeline spanning IL-17 (PN-881), obesity GLP-1/GIP/GCG candidates (PN-477, PN-458) and oral hepcidin (PN-8047) adds optionality.
Sources: SEC EDGAR (CIK 0001377121, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/21/2026, 8:54:37 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.